Afirma Thyroid Studies to Be Presented in November
Thyroid nodule patients and their doctors will see gene-expression research at the ATA meeting in Philadelphia.
Updated on Nov. 2, 2026 in Cancer
Veracyte, Inc. announced that 10 abstracts involving its Afirma thyroid test will be presented at the 2026 Annual Meeting of the American Thyroid Association, held November 4-7 in Philadelphia. The presentations include two oral talks and eight posters, and several studies are relevant to U.S. clinicians and patients evaluating thyroid nodules.
Why it matters
Thyroid nodules are common, and most are benign, so clinicians need tools that help separate harmless nodules from those that need surgery. Presenting this research at a major national endocrine meeting puts gene-expression-based diagnostic work in front of the specialists who manage these cases.
The evidence consists of ten abstracts submitted to the 2026 ATA Annual Meeting, a mix of two oral and eight poster presentations. Half of the studies were conducted independently of Veracyte, but the announcement does not report sample sizes or results, which will not be available until the presentations occur.
The players
Veracyte, Inc.
Nasdaq-listed cancer diagnostics company that develops the Afirma thyroid test and the GRID research database, based in South San Francisco, Calif.
American Thyroid Association
Professional society of thyroid clinicians and researchers that hosts an annual meeting presenting the latest work on thyroid disease diagnosis and treatment.
Phillip Febbo, M.D.
Chief scientific and medical officer of Veracyte, overseeing the company's clinical and scientific programs.
The details
The studies explore how gene expression can provide insights beyond individual genetic alterations to inform thyroid nodule diagnosis. Oral presentations come from Johns Hopkins and MD Anderson, while posters use the Veracyte Genomic Resource for Intelligent Discovery (GRID) research database to investigate preoperative diagnosis and recurrence risk.
Timeline
November 4-7, 2026: 2026 ATA Annual Meeting in Philadelphia
November 5, 2026: Oral and poster presentations at the meeting
November 6, 2026: Oral and poster presentations at the meeting
Health Landscape
Thyroid nodule evaluation in the United States has increasingly relied on molecular testing to reduce unnecessary surgeries for nodules that prove benign. These abstracts add to a growing body of research testing whether gene-expression tools can improve diagnostic accuracy and recurrence-risk assessment.
If you have a thyroid nodule and your doctor has recommended a biopsy with an uncertain result, it is reasonable to ask whether molecular testing is an option in your case. Any decision about testing or surgery should be made with your physician, based on your own history and findings.
The takeaway
Gene-expression diagnostics are being studied as a way to sharpen thyroid nodule decisions. If you are navigating a nodule, ask your physician how molecular testing might fit into your evaluation.
What happens next
The 2026 ATA Annual Meeting presentations take place November 5 and 6, 2026, when the oral and poster results will be shared publicly.
Further reading
For broader context on how thyroid cancer is diagnosed and treated, browse the Cancer section of We are Healthy.
Source note: This article includes information reported by The Manila times.
